Effects of Yoga on Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.

Int J Rheum DisOct 1, 2026
Clinical ResearchRheumatology

Abinaya Suresh, Shobana Ramaswamy, Santhi Silambanan et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effects of yoga on psychological function and inflammation in individuals with rheumatoid arthritis (RA). Eight randomized controlled trials involving 651 participants were analyzed. The results indicated that yoga significantly improved psychological outcomes, with a reduction in Disease Activity Score (DAS 28) of SMD = -0.44, and decreased serum Interleukin-6 levels (SMD = -0.65).

Key findings

  • Yoga significantly reduced Disease Activity Score (DAS 28) with SMD = -0.44; p < 0.0001.
  • Serum Interleukin-6 levels decreased significantly with yoga, SMD = -0.65; p = 0.03.
  • No significant changes were observed in Health Assessment Questionnaire (HAQ-DI) scores.
  • Changes in Tumor Necrosis Factor-alpha (TNF-α) were not statistically significant.

Why it matters

The findings suggest that yoga may be a beneficial adjunct therapy for improving mental health and reducing inflammation in patients with rheumatoid arthritis, potentially enhancing overall patient well-being.

Source

PubMed · PMID 42827396

Published in Int J Rheum Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Rheumatology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.